Chief Executive David Ricks told then-UK Health Secretary Victoria Atkins last December that the company’s new Alzheimer’s ...

The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...

Insitro has teamed up with Eli Lilly to help power programs into the clinic, tapping the Big Pharma for an option on ...